Waters Corporation (WAT)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$409.38-1.01%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · WAT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 8.6% |
| Our one-year growth estimate | diamond | 38.2% |
Growth built into the price is above our model estimate.
The price assumes 29.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
WAT — President transition
Dated 2026-08-21
Senior Vice President — Robert L. Carpio III: The Senior Vice President of a specific division resigned to pursue other opportunities, representing a genuine executive departure but not necessarily a shock to the entire company's leadership.
Why it matters: If revenue is above this amount, it shows good integration from the acquisition.
Supportive ifRevenue from acquired businesses is more than $895 million in Q3.
Worry ifRevenue from acquired businesses is less than $895 million in Q3.
Why it matters: This growth range shows if Waters can maintain its momentum after raising guidance. Strong growth indicates solid execution and market demand.
Supportive ifQ3 revenue growth in constant currency is between 8% and 10%.
Worry ifQ3 revenue growth in constant currency is below 8%.
Why it matters: Raising EPS guidance would show stronger profit expectations. This could boost investor confidence.
Supportive ifManagement raises the 2026 EPS guidance. It is now higher than before.
Worry ifManagement maintains or lowers the full-year 2026 EPS guidance.
Why it matters: This EPS range shows strong profits. It also shows management's confidence in earnings growth.
Supportive ifQ3 adjusted EPS reported between $3.95 and $4.05.
Worry ifQ3 adjusted EPS reported below $3.95.
Why it matters: Success in integration will affect revenue and growth.
Supportive ifManagement says they are hitting revenue goals from the Biosciences purchase.
Worry ifManagement reports delays or problems with revenue goals.
Why it matters: This guidance will help assess if Waters can continue to capitalize on market strength.
Supportive ifQ3 total revenue guidance is between $1.745 billion and $1.762 billion.
Worry ifQ3 total reported revenue guidance falls below $1.745 billion.
Why it matters: If integration works well, it will show the expected revenue gains from the BD deal.
Supportive ifRevenue gains from the BD deal will be over $35 million in 2026.
Worry ifRevenue synergies from the BD acquisition fall below $15 million in 2026.
Why it matters: This report will provide insights on performance and guidance. It could influence stock sentiment.
Watch forThe earnings report shows revenue and EPS above market expectations.
Also watch forThe earnings report shows revenue and EPS below market expectations.
Why it matters: A raise in EPS guidance shows confidence in earnings growth. It reflects strong operational performance and effective cost management.
Supportive ifFull-year 2026 adjusted EPS guidance confirmed at $14.45 to $14.65.
Worry ifFull-year 2026 adjusted EPS guidance is below $14.45.
Why it matters: This will show if the company can keep its recent growth in a tough market.
Watch forQ2 2026 total revenue exceeds $1.631 billion.
Also watch forQ2 2026 total revenue falls below $1.616 billion.
Why it matters: Maintaining this guidance is key for investor confidence in ongoing growth.
Supportive ifFull-year 2026 revenue guidance is still above $6.415 billion.
Worry ifFull-year 2026 revenue guidance is now below $6.415 billion.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$108 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $288 loss on $10,000 · 2.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,132 loss on $10,000 · 31.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.